HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Figures Buy All Versions of this Article: 297/2/H821    most recent 00345.2009v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Villeneuve, C. Articles by Mialet-Perez, J. Search for Related Content PubMed PubMed Citation Articles by Villeneuve, C. Articles by Mialet-Perez, J.

Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells

¹Institut National de la Santé et de la Recherche Médicale, U858, and ²Université de Toulouse, UPS, Institut de Médecine Moléculaire de Rangueil, Centre Hospitalier Universitaire de Toulouse, IFR31, Toulouse, France

Submitted 9 April 2009 ; accepted in final form 18 June 2009

There is substantial evidence supporting a hypertrophic action of serotonin [5-hydroxytryptamine (5-HT)] in cardiomyocytes. However, little is known about the mechanisms involved. We previously demonstrated that 5-HT-induced hypertrophy depends, in part, on the generation of reactive oxygen species by monoamine oxidase-A (MAO-A) (see Ref. 3). Cardiomyocytes express 5-HT₂ receptors, which may also participate in hypertrophy. Here, we analyzed the respective contribution of 5-HT₂ receptors and MAO-A in H9C2 cardiomyoblast hypertrophy. 5-HT induced a dose-dependent increase in [³H]leucine incorporation and stimulation of two markers of cardiac hypertrophy, ANF-luc and SK-actin-luc reporter genes. Experiments using 1 µM 5-HT showed that hypertrophic response occurred independently from MAO-A. Using pharmacological inhibitors (M100907 and ketanserin), we identified a novel mechanism of action involving 5-HT_2A receptors and requiring Ca²⁺/calcineurin/nuclear factor of activated T-cell activation. The activation of this hypertrophic pathway was fully prevented by 5-HT_2A inhibitors and was unaffected by MAO inhibition. When 10 µM 5-HT was used, an additional hypertrophic response, prevented by the MAO inhibitors pargyline and RO 41-1049, was observed. Unlike the 5-HT_2A-receptor-mediated H9C2 cell hypertrophy, MAO-A-dependent hypertrophic response required activation of extracellular-regulated kinases. In conclusion, our results show the existence of a dose-dependent shift of activation of distinct intracellular pathways involved in 5-HT-mediated hypertrophy of cardiac cells.

5-hydroxytryptamine; 5-hydroxytryptamine 2A; monoamine oxidase type A; hypertrophy